Compounded GLP-1 Ban: Novo and Lilly's FDA Push Explained

Novo Nordisk has formally asked the FDA to place semaglutide on the agency’s “Demonstrable Difficulties for Compounding” (DDC) lists — a step that would prohibit compounding pharmacies from making the molecule even during a future shortage. The request, reported by pharmaphorum on August 19, puts Novo alongside Eli Lilly in a coordinated push to end the compounded GLP-1 era for the two biggest molecules. For compounding pharmacies and peptide researchers, the question is no longer whether the pathway is closing, but how completely.

What Novo and Lilly are asking the FDA to do

Novo’s ask is specific: add semaglutide to the DDC lists — drugs that, while possibly in limited supply, are considered too complicated for compounders to make safely. Novo first filed the request in October 2024 (Docket FDA-2017-N-2562, via regulations.gov), arguing semaglutide meets all six FDA criteria — complex formulation, delivery mechanism, dosage form, bioavailability, compounding process, and analytic testing complexity. The company’s statement is blunt:

“These drugs are inherently complex to compound safely, and the risks they pose to patient safety far outweigh any benefits.” — Novo Nordisk

Eli Lilly has pushed a parallel track, asking the FDA to ban copies of its tirzepatide therapies (Mounjaro, Zepbound) and pressing cease-and-desist letters on compounding pharmacies, weight-loss clinics, and medical spas. Novo has filed more than a dozen legal actions since late 2023 and sued telehealth giant Hims & Hers over compounded semaglutide in February 2026.

The DDC mechanism is the permanent backstop: a drug on the lists cannot be compounded “regularly or in inordinate amounts” under section 503A — even when the approved product is unavailable.

The shortage premise is already gone

Some coverage frames the crackdown “despite” Wegovy and Ozempic still being in shortage. That premise is wrong. The FDA resolved the semaglutide injection shortage on February 21, 2025, and the tirzepatide shortage in late 2024. Neither molecule appears in the FDA Drug Shortage Database today; only Novo’s liraglutide (Victoza, Saxenda) remains “Currently in Shortage.”

This is not a response to an ongoing shortage — that pathway closed. The DDC and bulks-list requests would foreclose compounding even in a future shortage, and they protect patent economics: generics are blocked until at least 2032 (semaglutide) and 2036 (tirzepatide), per Stanford Medicine.

Three regulatory levers are closing at once

The FDA GLP-1 compounding crackdown is advancing on three levers at once:

1. The shortage list (already closed). Under FD&C Act sections 503A/503B, pharmacies could compound copies of approved drugs while on the shortage list. With both resolved, the FDA enforced phased wind-down deadlines through spring 2025, per its clarification page.

2. The 503B bulks list (backstop now — the court closed the primary lever). On April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding “no clinical need for outsourcing facilities to compound these drugs from bulk substances.” The public comment period closed June 29, 2026, with no final determination — see FDA Proposes Excluding GLP-1 Drugs From 503B Compounding List. On Aug 27, 2026, the Fifth Circuit upheld the FDA’s shortage delisting, which already ended shortage-based bulk compounding; if finalized, the 503B exclusion would make the ban permanent even in a future shortage.

“When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need.” — then-FDA Commissioner Marty Makary

3. The DDC lists (Novo’s ask, pending). If granted, semaglutide compounding would be prohibited under any circumstances — shortage or not. The FDA has not acted on the 2024 nomination.

What it means for compounding pharmacies

The 503B mass-compounding business model for these APIs is ending. Bulk compounding without individual prescriptions is exactly what the bulks-list exclusion would permanently close, “regardless of future market conditions.” The patient-specific 503A pathway remains technically available with a documented medical need, but enforcement is tightening there too — FDA warning letters and litigation over both shortage resolutions.

The industry’s trade body contests the framing. The Alliance for Pharmacy Compounding says Novo is “confusing the fact that the semaglutide molecule is demonstrably difficult to manufacture […] with the relative simplicity of compounding with it.” But the FDA’s guidance is unambiguous: “Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.”

The legal gray zones

What remains legal versus what was always gray:

• 503A patient-specific compounding survives, but only with a documented significant difference from the approved drug.
• “Research use only” peptides sit in a separate gray zone. Retatrutide and cagrilintide “cannot be used in compounding under federal law,” per the FDA, yet the research-supply market operates on labeling rather than enforcement — a gap state boards are beginning to fill (State Peptide Regulation Fills the Federal Oversight Gap).
• Safety data explains the urgency. The FDA logged more than 455 adverse event reports for compounded semaglutide and more than 320 for compounded tirzepatide as of early 2025, many involving dosing errors from multidose vials; Novo’s testing found up to 33% unknown impurities and at least 19% under-strength semaglutide.

The FDA’s peptide paradox

Here is the paradox: the GLP-1 ban push tightens while the FDA’s own Pharmacy Compounding Advisory Committee — with a Kennedy-overhauled roster — voted to allow compounding of four of the seven peptides under review on the first day of its July 23–24, 2026 meeting (BPC-157, KPV and TB-500 by 8–6 with one abstention, MOTS-c by 7–5 with two) and six of the seven in total, in per-substance votes against FDA staff advice, with HHS Secretary Robert F. Kennedy Jr. championing looser peptide rules (Healio, Jul 24, 2026, CNN, updated Jul 24, 2026). The same administration is easing compounding for BPC-157 and TB-500 while closing it for GLP-1s.

The distinction is clinical evidence — and that is the precedent that matters. The “no clinical need” logic used against GLP-1s applies even more forcefully to peptides with thinner evidence, a compliance consultant told PeptidesBeat in May. The PCAC recommendations are recommendations only: formal 503A bulks-list placement requires rulemaking, and the GLP-1 503B decision would set the template. Takeaway for suppliers: the gray market is not a safe harbor — enforcement expands even as the committee loosens.

What to watch

• The Aug 27, 2026 Fifth Circuit ruling — the panel upheld the FDA’s GLP-1 delisting, ending the last legal avenue for bulk compounding; patient-specific 503A compounding for documented medical needs remains lawful.
• The telehealth pricing response — on Aug 28, 2026, DirectMeds launched doctor-guided GLP-1 programs starting at $249/month (sublingual semaglutide; injectable from $297/month) with no membership fees, the latest transparent-priced program competing for patients who relied on cheap compounded supply. See our GLP-1 telehealth pricing in 2026 guide for the full provider-by-provider comparison. For how to read that comparison, see How to Tell If a GLP-1 Price Comparison Is Trustworthy.
• The FDA’s final decision on the 503B bulks-list exclusion — now a backstop that would keep the ban in place even during a future shortage.
• The FDA’s response to Novo’s DDC nomination (Docket FDA-2017-N-2562).
• The liraglutide shortage — when it resolves, the last shortage-based GLP-1 pathway closes.
• The Overton FDA nomination — the next commissioner inherits the 503B decision and the PCAC follow-through.

Bottom line

As of Aug 27, 2026, bulk compounding of semaglutide and tirzepatide for general use is no longer lawful: the Fifth Circuit upheld the FDA’s delisting, ending the last legal avenue for the shortage-based mass-compounding channel. Patient-specific 503A compounding for an individual with a documented medical need remains legal. The 503B bulks-list exclusion and a DDC listing would make the ban permanent even in a future shortage. The industry is being pushed toward patient-specific 503A compounding while enforcement tightens on one side and the advisory committee loosens on the other. Track the rulemaking calendar on our PCAC tracker and check the BPC-157 and TB-500 guides for each peptide’s legal status.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.